News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vexim Strengthens Its Management Structure With the Appointment of Jerome Marzinski as Deputy CEO



10/7/2013 8:58:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Vexim strengthens its management structure with the appointment of Jérôme Marzinski as Deputy CEO

Toulouse, October 9th 2013 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announced that Jérôme Marzinski will take up the position of Deputy CEO, as the company continues to show steady growth. Jérôme will contribute to bringing Vexim into its next phase of development, reporting to the CEO, Vincent Gardès.

Jérôme Marzinski is 40 years old and joins VEXIM as Deputy CEO. Jérôme has a financial background, having obtained a Masters in Finance from the University of Lille (1994) and an MBA from the HEC Business School in Paris (2012). Jérôme began his career as a financial analyst at SGI (1995–1997), then as Finance Manager with Hertz (1998–1999). Following that, he joined Sun Microsystems Inc., where he took up management positions from 2000 to 2007, in the United States, France, the United Kingdom and the Netherlands. In 2007, he became fully immersed in the domain of medical technologies when he joined ev3, a company specialising in vascular implants, as International Finance Manager and then as Europe GM, from 2009 to 2012, participating in the buyout of ev3 by the American group Covidien in 2010. Before joining Vexim in August 2013, Jérôme successfully carried out executive consulting missions for medtech companies’ managers and shareholders. He has a deep understanding of the business and has strong financial and operational knowledge of the constraints and the stakes at play in the medical device sector. Jérôme’s financial and managerial skills will allow him to support Vexim’s strong growth.

“We are glad to have Jérôme on board and the team will greatly benefit from his expertise and skills. His arrival shows our willingness to drive the company to its next stage, focused on rapid dynamic growth that brings value to our shareholders. As of today, we already have a direct presence in Europe’s 5 largest markets for the treatment of vertebral fractures and more than 6000 SpineJacks® have already been implanted”, commented Vincent Gardès, CEO of Vexim.

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital1 and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India, Taiwan and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3rd 2012.

For further information, please go to www.vexim.com

SpineJack®2, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

investisseur@vexim.com

NewCap.

Financial Communications and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 6 64 18 99 59 Christian Berg christian@alizerp.com Tel: +33 1 70 22 53 86

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Vexim
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES